Pfizer (PFE) closed at $43.57 in the latest trading session, marking a -0.84% move from the prior day. This move lagged the S&P 500's daily loss of 0.28%.

Prior to today's trading, shares of the drugmaker had lost 5.71% over the past month. This has lagged the Medical sector's loss of 2.31% and the S&P 500's loss of 0.56% in that time.

Investors will be hoping for strength from PFE as it approaches its next earnings release. In that report, analysts expect PFE to post earnings of $1.12 per share. This would mark year-over-year growth of 55.56%. Our most recent consensus estimate is calling for quarterly revenue of $22.5 billion, up 85.47% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $4.09 per share and revenue of $80.95 billion, which would represent changes of +84.23% and +69.91%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for PFE. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.56% higher. PFE is holding a Zacks Rank of #3 (Hold) right now.

In terms of valuation, PFE is currently trading at a Forward P/E ratio of 10.75. This valuation marks a discount compared to its industry's average Forward P/E of 13.28.

Also, we should mention that PFE has a PEG ratio of 1.53. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.02 at yesterday's closing price.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 113, which puts it in the top 45% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research